Expired activity
Please go to the PowerPak homepage and select a course.

Optimizing Outcomes in Invasive Fungal Disease: Interdisciplinary Perspectives

This activity is jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and The Mycoses Study Group Education & Research Consortium.
PIMTerranova Medica, LLCThe Mycoses Study Group Education & Research Consortium


This activity is supported by independent educational grants from Astellas; Merck & Co, Inc; Gilead Sciences Europe, Ltd; T2 Biosystems; MiraVista Diagnostics; and Viracor–IBT Laboratories.

FACULTY

Luis Ostrosky-ZeichnerLuis Ostrosky-Zeichner, MD, FACP, FIDSA, FSCHEA — Chair
Professor of Medicine and Epidemiology
Director, Mycology Research Laboratory
Medical Director for Epidemiology, Division of Infectious Diseases
University of Texas Medical School at Houston
Houston, Texas






Melissa D. JohnsonMelissa D. Johnson, PharmD
Associate Professor of Medicine
Division of Infectious Diseases and International Health
Duke University Medical Center
Durham, North Carolina







FINANCIAL DISCLOSURE

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

LUIS OSTROSKY-ZEICHNER, MD, FACP, FIDSA, FSHEA
RESEARCH SUPPORT:
Astellas; Pfizer, Inc.; Scynexis
ADVISORY BOARD:
Merck & Co, Inc.
CONSULTANT:
Astellas; Scynexis
SPEAKER'S BUREAU:
Merck & Co, Inc.; Pfizer, Inc.; T2 Biosystems
INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE:
Discussion of investigational agents and diagnostics for IFIs

MELISSA D. JOHNSON, PHARMD
RESEARCH SUPPORT:
Astellas; Charles River Laboratories; World Health Information Science Consultants
ADVISORY BOARD:
Astellas

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Lisa A. Tushla, PhD, H(ASCP), of Terranova Medica, LLC, reports no financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

ACCREDITATION STATEMENT

acpe Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: 0809-9999-16-080-H01-P

Credits: 2.0 hours (0.20 ceu)
Published: January 31, 2016
Expires:  January 31, 2017
Type of Activity: Knowledge

Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 120 minutes

TARGET AUDIENCE

This accredited activity has been designed for pharmacists.

HOW TO EARN CREDIT

During the period January 31, 2016 through January 31, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and the evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 75% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 75%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

GOAL

The goal of this activity is to support clinical pharmacists in their efforts to serve as expert members of the interdisciplinary care team in managing invasive fungal disease and improving patient outcomes.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

  1. Compare available and emerging therapies and diagnostics for management of IFD.
  2. Address pharmacologic considerations in optimal use of therapies for IFD.
  3. Select appropriate evidence-based antifungal diagnostics and therapies based on specific patient characteristics.
  4. Incorporate an interdisciplinary approach to the management of IFD, with the goal of improved antifungal stewardship.
  5. Provide accurate and appropriate counsel as part of the treatment team.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.